NanoSyrinx

NanoSyrinx is a synthetic biology company developing a next-generation platform technology for targeted intracellular delivery of biological molecules. The company engineers bacterial nanomachines called Nanosyringes, inspired by one of Nature's own elegant solutions, to enable targeted intracellular delivery of protein therapeutics such as antibodies and peptides. This addresses the critical challenge that over 80% of intracellular targets remain undruggable due to poor bioavailability. Building on over a decade of fundamental research, NanoSyrinx's platform aims to unlock the interior of the cell and the myriad therapeutic opportunities within. The company has been featured in Nature Biopharma Dealmakers and has attracted experienced biotherapeutics leadership including a CEO with 25+ years of experience who has secured over $500 million in funding. Founded in 2018 and headquartered in Coventry, United Kingdom, NanoSyrinx has raised $21.6M in Series A funding from investors including M Ventures, Octopus Ventures, IQ Capital, BGF, Lilly, and UK Innovation Science & Seed Fund.